Neurosense Therapeutics Ltd (NRSN)

05:14 AM

Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan

05:14 AM

Apr 04, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN

Apr 04, 2025

Apr 04, 2025

Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan

Apr 04, 2025

Mar 31, 2025

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com

Mar 31, 2025

Mar 27, 2025

NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks

Mar 27, 2025

Mar 25, 2025

Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com

Mar 25, 2025

Mar 24, 2025

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire

Mar 24, 2025

Mar 22, 2025

NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World

Mar 22, 2025

Mar 20, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire

Mar 20, 2025

Mar 19, 2025

NeuroSense Advances PrimeC Commercialization in Canada - TipRanks

Mar 19, 2025

Mar 17, 2025

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan

Mar 17, 2025

Feb 27, 2025

The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury

Feb 27, 2025

Feb 19, 2025

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks

Feb 19, 2025

Jan 14, 2025

NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks

Jan 14, 2025

Jan 14, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World

Jan 14, 2025

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost - Investing.com

Jan 06, 2025

Jan 06, 2025

NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria

Jan 06, 2025

Jan 06, 2025

NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks

Jan 06, 2025

Jan 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com

Jan 06, 2025

Jan 03, 2025

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com

Jan 03, 2025

Dec 31, 2024

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com

Dec 31, 2024

Dec 28, 2024

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com

Dec 28, 2024

Dec 25, 2024

Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail

Dec 25, 2024

Dec 24, 2024

Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World

Dec 24, 2024

Dec 23, 2024

NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks

Dec 23, 2024

Dec 23, 2024

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq

Dec 23, 2024

Dec 23, 2024

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World

Dec 23, 2024

Dec 23, 2024

NeuroSense Signs Binding Term Sheet With Global Pharma To Advance PrimeC For ALS Treatment - Nasdaq

Dec 23, 2024

Dec 18, 2024

NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks

Dec 18, 2024

Dec 18, 2024

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz

Dec 18, 2024

Dec 18, 2024

NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial - StockTitan

Dec 18, 2024

Dec 18, 2024

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt

Dec 18, 2024

Dec 17, 2024

NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks

Dec 17, 2024

Dec 17, 2024

NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World

Dec 17, 2024

Dec 16, 2024

Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa

Dec 16, 2024

Dec 16, 2024

Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com

Dec 16, 2024

Dec 15, 2024

Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World

Dec 15, 2024

Dec 13, 2024

NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia

Dec 13, 2024

Dec 11, 2024

NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks

Dec 11, 2024

Dec 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com

Dec 11, 2024

Dec 11, 2024

NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com

Dec 11, 2024

Dec 11, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com

Dec 11, 2024